Bristol-Myers rolls out hepatitis B drug for marketing in India

[Guest guest]

Article Summary

Bristol-Myers rolls out hepatitis B drug

Business Standard - 11-Jul-2006

The new product, an oral antiviral therapy specifically designed to block

the replication of Hepatitis B virus (HBV) in the liver, is indicated for

the treatment of chronic Hepatitis B virus infection in adults. Chronic

Hepatitis B infection is a potentially life-threatening disease with more

than half a million people worldwide die each year from hepatocellular

carcinoma (HCC), a cancer caused by chronic Hepatitis B.

Summary

• Baraclude, an entecavir oral formulation for the treatment of chronic

Hepatitis B virus infection was approved by the Drug Controller General of

India (DCGI) recently, for marketing in India.

• Baraclude is one of the important prescription drugs from the BMS'global

portfolio.

• The drug is available in tablet form in India, which would cost about Rs

208 per tablet.

• The new product, an oral antiviral therapy specifically designed to block

the replication of Hepatitis B virus (HBV) in the liver, is indicated for

the treatment of chronic Hepatitis B virus infection in adults.

• Chronic Hepatitis B infection is a potentially life-threatening disease

with more than half a million people worldwide die each year from

hepatocellular carcinoma (HCC), a cancer caused by chronic Hepatitis B.

• India has intermediate endemicity for Hepatitis B infection with

prevalence for chronic infection of 4 per cent.

• An estimated 36 million people are chronically infected with the Hepatitis

B virus, most of which are established during early childhood.

• Hepatitis B infection is reported to be responsible for 80 per cent of the

cases of cirrhosis of the liver and 60 per cent of HCC.

_________________________________________________________________

Don’t just search. Find. Check out the new MSN Search!

http://search.msn.click-url.com/go/onm00200636ave/direct/01/

[Guest guest]

Article Summary

Bristol-Myers rolls out hepatitis B drug

Business Standard - 11-Jul-2006

The new product, an oral antiviral therapy specifically designed to block

the replication of Hepatitis B virus (HBV) in the liver, is indicated for

the treatment of chronic Hepatitis B virus infection in adults. Chronic

Hepatitis B infection is a potentially life-threatening disease with more

than half a million people worldwide die each year from hepatocellular

carcinoma (HCC), a cancer caused by chronic Hepatitis B.

Summary

• Baraclude, an entecavir oral formulation for the treatment of chronic

Hepatitis B virus infection was approved by the Drug Controller General of

India (DCGI) recently, for marketing in India.

• Baraclude is one of the important prescription drugs from the BMS'global

portfolio.

• The drug is available in tablet form in India, which would cost about Rs

208 per tablet.

• The new product, an oral antiviral therapy specifically designed to block

the replication of Hepatitis B virus (HBV) in the liver, is indicated for

the treatment of chronic Hepatitis B virus infection in adults.

• Chronic Hepatitis B infection is a potentially life-threatening disease

with more than half a million people worldwide die each year from

hepatocellular carcinoma (HCC), a cancer caused by chronic Hepatitis B.

• India has intermediate endemicity for Hepatitis B infection with

prevalence for chronic infection of 4 per cent.

• An estimated 36 million people are chronically infected with the Hepatitis

B virus, most of which are established during early childhood.

• Hepatitis B infection is reported to be responsible for 80 per cent of the

cases of cirrhosis of the liver and 60 per cent of HCC.

_________________________________________________________________

Don’t just search. Find. Check out the new MSN Search!

http://search.msn.click-url.com/go/onm00200636ave/direct/01/

[Guest guest]

Article Summary

Bristol-Myers rolls out hepatitis B drug

Business Standard - 11-Jul-2006

The new product, an oral antiviral therapy specifically designed to block

the replication of Hepatitis B virus (HBV) in the liver, is indicated for

the treatment of chronic Hepatitis B virus infection in adults. Chronic

Hepatitis B infection is a potentially life-threatening disease with more

than half a million people worldwide die each year from hepatocellular

carcinoma (HCC), a cancer caused by chronic Hepatitis B.

Summary

• Baraclude, an entecavir oral formulation for the treatment of chronic

Hepatitis B virus infection was approved by the Drug Controller General of

India (DCGI) recently, for marketing in India.

• Baraclude is one of the important prescription drugs from the BMS'global

portfolio.

• The drug is available in tablet form in India, which would cost about Rs

208 per tablet.

• The new product, an oral antiviral therapy specifically designed to block

the replication of Hepatitis B virus (HBV) in the liver, is indicated for

the treatment of chronic Hepatitis B virus infection in adults.

• Chronic Hepatitis B infection is a potentially life-threatening disease

with more than half a million people worldwide die each year from

hepatocellular carcinoma (HCC), a cancer caused by chronic Hepatitis B.

• India has intermediate endemicity for Hepatitis B infection with

prevalence for chronic infection of 4 per cent.

• An estimated 36 million people are chronically infected with the Hepatitis

B virus, most of which are established during early childhood.

• Hepatitis B infection is reported to be responsible for 80 per cent of the

cases of cirrhosis of the liver and 60 per cent of HCC.

_________________________________________________________________

Don’t just search. Find. Check out the new MSN Search!

http://search.msn.click-url.com/go/onm00200636ave/direct/01/

[Guest guest]

Article Summary

Bristol-Myers rolls out hepatitis B drug

Business Standard - 11-Jul-2006

The new product, an oral antiviral therapy specifically designed to block

the replication of Hepatitis B virus (HBV) in the liver, is indicated for

the treatment of chronic Hepatitis B virus infection in adults. Chronic

Hepatitis B infection is a potentially life-threatening disease with more

than half a million people worldwide die each year from hepatocellular

carcinoma (HCC), a cancer caused by chronic Hepatitis B.

Summary

• Baraclude, an entecavir oral formulation for the treatment of chronic

Hepatitis B virus infection was approved by the Drug Controller General of

India (DCGI) recently, for marketing in India.

• Baraclude is one of the important prescription drugs from the BMS'global

portfolio.

• The drug is available in tablet form in India, which would cost about Rs

208 per tablet.

• The new product, an oral antiviral therapy specifically designed to block

the replication of Hepatitis B virus (HBV) in the liver, is indicated for

the treatment of chronic Hepatitis B virus infection in adults.

• Chronic Hepatitis B infection is a potentially life-threatening disease

with more than half a million people worldwide die each year from

hepatocellular carcinoma (HCC), a cancer caused by chronic Hepatitis B.

• India has intermediate endemicity for Hepatitis B infection with

prevalence for chronic infection of 4 per cent.

• An estimated 36 million people are chronically infected with the Hepatitis

B virus, most of which are established during early childhood.

• Hepatitis B infection is reported to be responsible for 80 per cent of the

cases of cirrhosis of the liver and 60 per cent of HCC.

_________________________________________________________________

Don’t just search. Find. Check out the new MSN Search!

http://search.msn.click-url.com/go/onm00200636ave/direct/01/